XSHG
600998
Market cap3.81bUSD
Oct 09, Last price
5.08CNY
1D
0.40%
1Q
1.40%
Jan 2017
-48.89%
IPO
-39.38%
Name
Jointown Pharmaceutical Group Co Ltd
Chart & performance
P/E
11.36
P/S
0.16
EPS
0.45
Div yield, %
3.95%
Shrs. gr., 5y
-0.81%
Rev. gr., 5y
7.80%
Revenues
161.39b
+6.31%
Net income
2.25b
-10.07%
CFO
3.44b
+11.62%
Dividend
Jun 08, 20260.2 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jointown Pharmaceutical Group Co., Ltd engages in pharmaceutical distribution and supply chain business in China and internationally. It is also involved in general agency brand promotion; pharmaceutical industrial self-production and OEM; and pharmaceutical new retail and ten-thousand store alliance plan businesses. In addition, the company provides medical health and technology value-added services; and digital logistics and supply chain solutions. The company was founded in 1999 and is headquartered in Wuhan, China.
Key people
Yichang Liu
Business President, Vice Chairman of the Board · since 2024
Yihua Gong
Vice Chairman of the Board, General Manager · since 2024
Zhaonian Liu
Vice Chairman of the Board · since 2011
Xiaoyi Xia
Chief Financial Officer · since 2023
Wei He
Vice President, Director · since 2024
Weijun Chen
Deputy General Manager · since 2023
Lei Guo
Deputy General Manager · since 2011
Jinghan Liu
Deputy General Manager · since 2021
Ming Quan
Deputy General Manager · since 2020
Qibing Wang
Deputy General Manager · since 2023
Deputy General Manager · since 2023
Nie Yang
Deputy General Manager, General Manager - Hospital Business Division · since 2021
Jumei Yang
Deputy General Manager · since 2016
Qingsong Zhang
Deputy General Manager · since 2021
Zhifeng Liu
Deputy General Manager, Secretary of the Board · since 2022
Dengpan Liu
Vice Chairman of the Board · since 2020
Changyun Liu
Chairman of the Board · since 2020
Qi Wang
Director · since 2008
Xuesong Wu
Director · since 2020
Hua Ai
Independent Director · since 2020
Headquarters & legal address
湖北省武汉市汉阳区龙阳大道特8号
武汉市, HB 100000
CN
武汉市, HB 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||